ProMIS Neurosciences, Inc.
PMN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | -0.00 | 0.34 |
| FCF Yield | -68.71% | -22.85% | -20.32% | -24.94% |
| EV / EBITDA | 0.05 | -1.22 | -2.16 | -82.78 |
| Quality | ||||
| ROIC | -127.07% | 3,237.43% | -77.79% | -35.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.38 | 0.67 | 34.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -164.18% | 21.77% | 40.16% | -23.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.33 | 0.45 | 1.14 | 55.80 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |